Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CENP-V as a Potential Diagnostic Marker of Damage in Human Oocytes

NCT06788379 is registered in ClinicalTrials.gov with Vida Recoletas Sevilla as lead sponsor.

NCT NCT06788379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CENP-V as a Potential Diagnostic Marker of Damage in Human Oocytes
Lead sponsor
Vida Recoletas Sevilla
Phase
Observational
Overall status
Recruiting
Start date
October 4, 2024
Completion date
December 31, 2027
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advance maternal age, establish the amount of cenpv protein in human oocytes as a diagnostic tool against damage caused by ageing or by the procedure of vitrification of oocytes, vitrification and thawing